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Abstract
Background: Previous genetic analysis has shown that a deletion in the complement component
5 gene-coding region renders mice more susceptible to allergen-induced airway
hyperresponsiveness (AHR) due to reduced IL-12 production. We investigated the role of
complement in a murine model of asthma-like pulmonary inflammation.
Methods: In order to evaluate the role of complement B10 mice either sufficient or deficient in
C5 were studied. Both groups of mice immunized and challenged with a house dust extract (HDE)
containing high levels of cockroach allergens. Airways hyper-reactivity was determined with whole-
body plesthysmography. Bronchoalveolar lavage (BAL) was performed to determine pulmonary
cellular recruitment and measure inflammatory mediators. Lung homogenates were assayed for
mediators and plasma levels of IgE determined. Pulmonary histology was also evaluated.
Results: C5-deficient mice showed enhanced AHR to methylcholine challenge, 474% and 91%
increase above baseline Penh in C5-deficient and C5-sufficient mice respectively, p < 0.001. IL-12
levels in the lung homogenate (LH) were only slightly reduced and BAL IL-12 was comparable in
C5-sufficient and C5-deficient mice. However, C5-deficient mice had significantly higher cysteinyl-
leukotriene levels in the BAL fluid, 1913 +/- 246 pg/ml in C5d and 756 +/- 232 pg/ml in C5-sufficient,
p = 0.003.
Conclusion:  These data demonstrate that C5-deficient mice show enhanced AHR due to
increased production of cysteinyl-leukotrienes.
Background
The incidence and severity of allergic asthma has been
steadily rising over the past 20 years. Allergic asthma
results from an inappropriate immune response to
inhaled allergens characterized by the recruitment of eosi-
nophils, lymphocytes, and neutrophils to the lung,
inflammatory mediator release, IgE production, mucin
hypersecretion and bronchoconstriction. It is believed
that CD4+ Th2-type cells mediate these responses through
the production of the cytokines IL-4, IL-5, IL-9 and IL-13
(Reviewed in [1]).
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Recent studies have shown that patients with asthma have
increased activation of complement components C3 and
C5 with increased bronchalveolar lavage C3a and C5a lev-
els following allergen challenge [2] and patients with
severe asthma have higher C3a plasma levels than those
with stable asthma. Numerous studies investigating the
role of C3 in asthma have shown C3-deficient mice have
consistently decreased AHR [3-6]. Studies by Drouin et al
found C3-deficent mice have decreased airway eosi-
nophilia, allergen-specific IgE and a reduced number of
IL-4 producing cells [6]. Converse to these studies genetic
analysis has inversely linked gene expression of comple-
ment component 5 (C5) with susceptibility to AHR in
mice [7]. In these studies mouse strains that are more sus-
ceptible to allergen-induced AHR had decreased C5 gene
expression while those resistant to developing AHR had
increased C5 gene expression. Few studies have further
investigated this paradigm.
In the present studies, C5-sufficient and C5-deficient con-
genic mice were immunized and challenged with a HDE
containing high levels of cockroach allergens (CRA). CRA
has been implicated as a key allergen in the incidence and
severity of allergic asthma [8]. We show that C5-deficient
mice have significantly increased AHR. C5-deficient mice
also have a dramatic increase in BAL fluid cysteinyl-leuko-
triene production providing a potential mechanism for
the increased AHR seen in these mice.
Materials and methods
Animals
6–8 week old C5-deficient (B10.D2-H2d H2T18c Hc0/
oSnJ) and C5-sufficient (B10.D2-H2d H2T18c Hc1/nSnJ)
congenic mice were purchased from Jackson Labs (Bar
Harbor, Maine). C5-deficient mice carry a null hemolytic
component (Hc) allele rendering them unable to produce
C5 [9,10]. Animals were kept under standard laboratory
conditions in a temperature-controlled room with a 12-
hour light/dark cycle and allowed food and water ad libi-
tum. All experiments have been approved by the Univer-
sity of Michigan Animal Use Committee.
House dust collection and extraction
Dust was collected from the kitchen area of homes of asth-
matic children using a vacuum with a dust collector
(Indoor Biotech, Charlottesville, VA). Sterile PBS was
added to the dust and mixed overnight at 4° on a rotator.
Samples were centrifuged for 10 minutes at 1000 × g, 4°C.
The supernatant was collected and centrifuged for 10 min-
utes at 1000 × g, 4°C and the HDE was stored in aliquots
at -70°C for analysis of allergen content[11] The levels of
cockroach allergens Bla g1 and Bla g2 in the HDE were
determined using matched-antibody pairs (Indoor Bio-
technologies, Charlottesville, VA). HDE contains 1,052-
ng/ml Bla g1 and 1,571-ng/ml Bla g2. HDE was diluted
1:10 and heat-inactivated for 30 minutes at 57°C prior to
use.
Induction of asthma
HDE diluted 1:10 in sterile PBS was emulsified in Titer-
Max Gold adjuvant (1:1, CytRx, Norcross, GA). 100 µl of
HDE:adjuvant was injected i.p. on day 0. On days 14 and
21 animals were challenged intratracheally with 1:10
diluted HDE, as previously described [11]. Briefly, mice
were anesthetized with isoflurane (Baxter, Deerfield, IL)
and the anesthetized mouse was suspended from its front
incisors on an inclined board with the base of the tail
taped to support its weight. The tongue was retracted
using forceps while holding the jaw open and two, 25 µl
aliquots of 1:10 diluted HDE were pipetted at the base of
the oropharynx. Mice were sacrificed by cervical disloca-
tion on day 22 or 23, as indicated in the text. Following
exsanguination, lungs were lavaged with 2, 1-ml fractions
of HBSS. The two washes were centrifuged at 1000-× g for
5 minutes. The supernatant of the first wash was saved for
later analysis while the supernatant of the 2nd fraction was
discarded. The cell pellets from both washes were com-
bined and total cells were counted using a Coulter counter
model ZF (Coulter Electronics, Hialeah, FL). Slides of BAL
fluid cells were prepared in a cytospin (Shandon Southern
Instruments, Sewickley, PA), slides were stained with Diff-
Quick (Baxter, Detroit, MI) and differentials were calcu-
lated by counting 300 cells. For lung homogenate prepa-
rations, the whole right lung was removed and kept on ice
in 3-ml of Hanks balanced salt solution without magne-
sium or calcium containing one Complete protease inhib-
itor tablet (Roche, Mannheim, Germany) and 0.01%
Triton-X. Samples were homogenized, sonicated and cen-
trifuged at 16,000-× g for 15 minutes at 4°C. Supernatant
was stored at -70°C for later protein determination.
Airway hyperresponsiveness
AHR of mice was measured 24-hours after the last airway
challenge using a whole-body plesthysmography system
(Buxco, Troy, NY). Mice were placed in the main chamber
and allowed to acclimate for 10 minutes. Baseline values
were then recorded for 5 minutes. Mice were subsequently
challenged with aerosolized PBS or increasing doses of
aerosolized β-methylcholine (Sigma, St. Louis, MO) for a
2-minute period. The response was recorded for 5 minutes
after each dose by measuring the pressure differences
between the main chamber containing the mouse and a
reference chamber. Differences in signal quantified during
respiratory cycle are reflected by enhanced pause (Penh).
Penh is widely used in models of pulmonary dysfunction
and has been shown to correlate with airway resistance
[12].
Penh values are normalized as the percent increase of
average Penh for each methylcholine dose over the aver-Respiratory Research 2006, 7:129 http://respiratory-research.com/content/7/1/129
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age Penh for PBS aerosolization. Calculating the change in
Penh will account for pressure changes resultant from
heating and humidification of air traveling between the
chamber and lungs, termed gas conditioning. If gas condi-
tioning is present, then an absolute Penh may not be
indicative of bronchial constriction [13]. Our experimen-
tal design ensures that the Penh does reflect increases in
bronchial constriction.
Leukotriene receptor antagonist treatment protocol
Immunized, C5-deficient mice were by oro-gavage with
10 mg/kg body weight of Montelukast (Singular®, Merck,
Whitehouse station, NJ) in 0.1 ml of PBS. The gavage was
performed with plastic gastric feeding needle (Instech,
Plymouth Meeting, PA) one hour before each pulmonary
challenge on days 14 and 21. Control mice received 0.1
ml of PBS.
Histology
Lungs were fixed in 10% neutral buffered formalin and
processed in paraffin. Slides were prepared, stained with
hematoxylin and eosin and evaluated in a blinded man-
ner by a board certified pathologist (DGR).
Cytokine, IgE and tryptase ELISAs
Lung homogenate and BAL fluid protein levels were
assessed as previously described [14]. CCL11, CCL2, IL-12
and IL-13 primary and secondary antibodies and stand-
ards were purchased from (R & D systems, Minneapolis,
MN). IL-12 was measured using antibodies directed
against the p70 form (also from R & D Systems). Total
plasma IgE was measured by ELISA using rat anti-mouse
IgE MAb, rat anti-mouse IgE biotinylated antibody, and
mouse IgE standard (Pharmingen, San Diego, CA). Stand-
ards and samples were diluted in dilution buffer contain-
ing 10% Casein, 0.05% Tween 20 and 0.0001% BSA in 1×
PBS. HRP-conjugated streptavidin (Jackson ImmunoRe-
seach Laboratories, West Grove, PA) was diluted 1:20,000
and added to plates for 30 minutes at room temperature.
Color was developed with 3, 3'-5, 5' tetramethylbenzidine
and the reaction was stopped with 1.5 M H2SO4. Plates
were read at 465 and 590 nm in a microplate reader (Bio-
Tek Instruments, Winooski, VT).
Mouse tryptase was measured by direct ELISA. Anti mouse
Tryptase  β-1 capture antibody and mouse tryptase β-1
standards were purchased from R&D Systems, Inc. (Min-
neapolis, MN). Ninety-six well plates (Nunc Immuno-
plate Maxisorb; Nunc, Neptune, NJ) were coated with
serially diluted standard or samples, and incubated over-
night at room temperature. The plates were then washed
using a wash buffer containing 0.05% Tween 20 (Fisher-
Biotech, Fair Lawn, NJ) in PBS. Nonspecific binding sites
were blocked by incubating the plates with Blocker Casein
(Pierce, Rockford, IL) in PBS for 1 hour. This and subse-
quent incubations were conducted at room temperature
on a shaker. After washing, the capture antibody was
added and the plates incubated for 2 h. Standard curves
were prepared using the appropriate recombinant aller-
gen. All standard and sample dilutions were made in dilu-
tion medium (10% casein in PBS supplemented with
0.1% bovine serum albumin and 0.05% Tween 20 (Fish-
erBiotech)). Plates were washed and peroxidase-conju-
gated mouse anti-rat IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA) was added to each well.
Plates were incubated for 1 h. After a final wash, 3,3',5,5'
tetramethylbenzidine(Genzyme Diagnostics, San Carlos,
CA) was added, plates wereincubated in the dark for 15
min, and the reaction was stopped with 1.5 N H2SO4.
Plates were read using dual wavelengths (465 and 590
nm) on the Bio-Tek microplate reader (Bio-Tek Instru-
ments, Winooski, VT), and allergen concentrations were
estimated using the recombinant allergen standard curve.
The lower limit of detection was 1.0 ng/ml.
Cysteinyl-leukotriene enzyme immunoassay
Leukotriene levels in BAL fluid were measured by Enzyme
Linked Immunoassay (Cayman Chemicals, Ann Arbor,
MI) at different dilutions as recommended by the Cayman
protocol. Only %B/B0 values in the linear range were
accepted, samples out of range were re-run at higher dilu-
tions.
C3 ELISA
96-well plates were coated with 50 µl rat anti-mouse C3
MAb (1:50 in PBS, Cell Sciences, Canton, MA) overnight
at 4°C. Plates were blocked with 150 µl of 2% bovine
serum albumin (BSA). Samples were diluted either 1:10
or 1:50 in dilution buffer containing 0.05% Tween 20
(FisherBiotech, Fair Lawn, NJ) and 2% fetal bovine serum
and 50 µl of sample in duplicate were added to the plate.
50  µl of rabbit anti-mouse C3 PAb (1:50 in dilution
buffer, Cell Sciences, Canton, MA) was added after wash-
ing. Plates were washed and 50 µl of goat anti-rabbit IgG-
HRP (1:5000 in dilution buffer, Jackson ImmunoRe-
search Laboratories, West Grove, PA) was added. With the
exception of coating antibody, all incubations were for
one hour at room temperature. Color was developed with
3,3',5,5' tetramethylbenzidine and the reaction was
stopped with 1.5 N H2SO4. Plates were read at 465 and
590 nm in a microplate reader (Bio-Tek Instruments,
Winooski, VT).
Statistical analysis
Student t tests were performed using GraphPad Prism ver-
sion 4.0 (GraphPad Software, San Diego, CA). Values are
expressed as mean ± SEM; p < 0.05 was considered signif-
icant.Respiratory Research 2006, 7:129 http://respiratory-research.com/content/7/1/129
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Results
C5-deficient mice have reduced pulmonary cell 
recruitment
House dust extracted in PBS and shown to contain high
levels of cockroach allergens results in pulmonary inflam-
mation, AHR and increased levels of lung CCL11, and
plasma IgE in a mouse model of allergic asthma [11,15].
Non-immunized, i.e. naïve, C5-sufficient and C5-defi-
cient mice had equivalent numbers of cells recovered
from the BAL fluid. These cells were 99% alveolar macro-
phages (data not shown). C5-deficient and C5-sufficient
congenic mice were immunized and challenged with
HDE. AHR was assessed by whole body plethysmography
on day 22, 24-hours after the last pulmonary challenge in
all experiments. For the 24-hour time point animals were
sacrificed immediately after AHR measurement. In sepa-
rate experiments mice were sacrificed 48-hours following
the last pulmonary challenge, on day 23; previous studies
have shown AHR peaks at 24-hours, whereas 48-hours is
the optimal time-point for eosinophil and lymphocyte
influx to the airways in this model system [11,15]. Differ-
ential counting of the BAL fluid found C5-deficient mice
exhibit slightly reduced total cell recruitment to the lung
following allergen challenge (Figure 1A). Eosinophil
influx to the airways is reduced in C5-deficient animals
compared to sufficient controls, though this reduction did
not reach significance (p = 0.06, Figure 1B). BAL fluid
lymphocytes, macrophages, and neutrophils were compa-
rable in the deficient and sufficient mice (Figure 1C–E).
Pulmonary inflammation was also comparable between
groups of animals as depicted in representative histology
from an immunized and challenged C5-sufficient (Figure
2A) and deficient (Figure 2B) animal 24-hours following
the last airway challenge. Blinded review of the histology
slides did not indicate any significant differences between
the groups. Fitting with the eosinophil influx to the air-
ways C5-deficient mice had slightly lower levels of lung
CCL11 (formerly eotaxin) in response to HDE challenge
compared to sufficient controls; 2,488 ± 360 vs. 1376 ±
524 pg/ml at 24-hours (Figure 3A). Levels of the chemoat-
tractant CCL2 (formerly MCP-1) followed a similar pat-
tern (Figure 3B).
Airway hyperresponsiveness is significantly increased in 
C5-deficient mice
Non-immunized C5-sufficient and C5-deficient animals
showed no difference in their response to 25 mg/ml of
MCh (data not shown, 0.4 ± 2.3% increase above baseline
Penh for C5-sufficient and 3.9 ± 2.8% for C5-deficient, n
= 8). Mice were then immunized and challenged and AHR
measured on day 22, 24-hours following the last pulmo-
nary challenge. In accordance with the reports from the
gene linkage studies, [7] C5-deficient mice had exacer-
bated hyperresponsiveness to a MCh challenge (Figure 4).
The data is reported as a percent increase in the average
Penh for each dose of nebulized MCh compared to neb-
ulized PBS. A nebulized dose of 25 mg/ml β-Mch resulted
in a 64 percent increase in Penh compared to nebulized
PBS, nearly 3-fold higher than the percent increase in
Penh of C5-sufficient mice (22 ± 5.9 percent increase, p =
0.0026). The exacerbated response in C5-deficient mice
was even more pronounced when mice were challenged
with 50 mg/ml β-Mch; 91 ± 19 vs. 474 ± 72 percent
increase in C5-sufficient and C5-deficient mice respec-
tively, p < 0.0001. Additional evidence of an increased
pulmonary response in the C5 deficient mice was docu-
mented by measuring tryptase within the bronchoalveolar
lavage fluid. The tryptase levels were found to be signifi-
cantly elevated in the C-5 deficient animals (Figure 5).
C5-deficient and sufficient mice produce comparable 
levels of BAL fluid IL-12
Th2-type cytokines are believed to mediate a substantial
portion of the phenotype observed in allergic asthma. It
has been suggested that decreased production of the Th1-
type cytokines IFN-γ and IL-12 skews the immune
response to a more Th2-type response increasing suscepti-
bility to allergic disorders (Reviewed in [1]). Previous in
vitro studies have shown that addition of a C5a receptor
antagonist to primary human monocyte cultures dose-
dependently inhibited the production of the Th1 cytokine
IL-12 [7]. In order to determine if C5-deficient mice had a
skewed immune response due to lack of IL-12 production
the levels of IL-12 were measured in the BAL fluid and
lung homogenate 24 and 48 hours after the last pulmo-
nary challenge. As shown in Figure 6A, lung homogenate
IL-12 was significantly reduced in C5-deficient mice at the
24-hour time point and remained lower than sufficient
animals at 48-hours. However, C5-deficient mice had BAL
fluid IL-12 levels comparable to C5-sufficient mice at both
24 and 48 hours following the last pulmonary challenge
(Figure 6B). IL-13 levels in the lung homogenate were also
similar at both 24 and 48 hours after allergen challenge
(Figure 6C); BAL fluid IL-13 was below detectable limits
at these time points. These data suggest that C5-deficient
animals do not have a skewed immune response favoring
the allergic phenotype.
One potential mechanism for the enhanced AHR in defi-
cient animals is a compensatory increase in C3 activation
resulting in mediator release from mast cells and
basophils. Enhanced C3 activation would result in
decreased levels of C3. However, C3 levels in the BAL fluid
were comparable in C5-sufficient and deficient animals at
24- and 48-hours post-allergen challenge (Figure 7); due
to limited sample plasma levels of C3 were not deter-
mined.Respiratory Research 2006, 7:129 http://respiratory-research.com/content/7/1/129
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BAL fluid differential Figure 1
BAL fluid differential. A cell differential was performed by counting of 300 cells on prepared cytospin slides from C5-sufficient 
(solid bars) and C5-deficient (diagonal bars) mice. A. Total Cells; B. Eosinophils, p = 0.0618 at 48-hours; C. Lymphoctyes; D. 
Macrophages; E. Neutrophils. Each value is the mean ± SEM for three experiments; n = 5 mice/group at 24-hours and n = 10 
mice/group at 48-hours. p > 0.05 for C5-sufficient compared to C5-deficient at each time point.
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Enhanced cysteinyl-leukotriene levels in the BAL fluid of 
C5-deficient mice
Cysteinyl-leukotrienes have been implicated as a key
mediator in the phenotype associated with allergic
asthma including increased bronchoconstriction and
mucin production [16,17]. Both C5a and C3a have recep-
tors on mast cells and basophils and can activate these
cells to release histamine and leukotrienes [18-21]. There-
fore, it would be expected that animals deficient in C5
exhibit decreased leukotriene secretion and AHR. Since
these animals have exacerbated airway responses to HDE
we sought to determine the levels of cysteinyl-leukot-
rienes in the BAL fluid of deficient and sufficient mice fol-
lowing allergen provocation. Leukotriene levels measured
at both 24- and 48-hours after the last pulmonary chal-
lenge were found to be significantly increased in C5-defi-
cient mice (Figure 8A). C5-deficient mice had a 4-fold
increase in cysteinyl-leukotiene secretion at 24-hours and
this exacerbated response was still seen at 48-hours with a
more than two-fold increase in BAL fluid leukotrienes in
deficient animals (756 ± 232 vs. 1913 ± 246 pg/ml in C5-
sufficient and C5-deficient mice respectively, p = 0.003).
This enhanced leukotriene production was not the result
of increased levels of IgE. C5-deficient mice had slightly
lower plasma IgE levels than C5-sufficient mice (Figure
8B). Cockroach allergen specific IgE could not be meas-
ured due to lack of specific reagents.
Chemokine production Figure 3
Chemokine production. Lung homogenate CCL2 and CCL11 
were determined by ELISA. C5-sufficient (solid bars), C5-
deficient (diagonal bars). Each value is the mean ± SEM for 
three experiments; n = 5 mice/group at 24-hours and n = 10 
mice/group mice at 48-hours, p > 0.05 for C5-sufficient com-
pared to C5-deficient at each time point.
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Histology Figure 2
Histology. Representative H&E stained sections from C5-suf-
ficient (A) and C5-deficient (B) animals that had been immu-
nized and challenged with HDE and sacrificed 24-hours after 
the last airway challenge. Images depicted at 20×.Respiratory Research 2006, 7:129 http://respiratory-research.com/content/7/1/129
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Leukotriene receptor antagonist prevents the augmented 
AHR in C5-deficient mice
To prove a cause and effect relationship between the ele-
vated pulmonary leukotriene concentrations and the
enhanced AHR in the C5-deficient mice, animals were
treated with the specific leukotriene receptor antagonist
montelukast 1 hour prior to pulmonary challenge with
the house dust extract. Blockade of the leukotriene recep-
tor resulted in a substantial reduction in AHR. In contrast,
none of the mice treated with vehicle had a decrease in
AHR (Figure 9).
Discussion
The role of the complement system in allergic asthma has
recently become an area of intense investigation [22].
Complement activation in allergic asthma may occur
through the classical, lectin, or alternative pathways; these
pathways converge at the level of C3 activation. The ana-
phylatoxins C3a and C5a may also be formed by proteo-
lytic cleavage of C3 and C5 by inflammatory cell-derived
proteases or allergen proteases [22-24]. Dendritic cells,
eosinophils, neutrophils, and T lymphocytes chemotax to
C5a [25-28]. Furthermore, C5a mediates eosinophil and
neutrophil activation resulting in degranulation and oxi-
dant secretion [27]. In our studies, cell recruitment to the
lung was not markedly decreased in C5-deficient animals
suggesting the involvement of other chemotactic agents.
Although these chemokines may account for allergen-
induced cellular influx in these animals, levels of the
chemotactic cytokines CCL11/eotaxin and CCL2/MCP-1
were not altered in C5-deficient animals. CCL11/eotaxin
has been shown to be a potent eosinophil chemotactic
mediator and is believed to be important in the develop-
ment of allergic asthma and is a major eosinophil chem-
oattractant in our model [11,29,30]. Despite comparable,
if not slightly reduced, pulmonary inflammation AHR
was exacerbated in C5-deficient animals indicating the
increased AHR in C5-deficient mice occurs independent
of cellular recruitment to the airways. Previous work in
our laboratory has suggested AHR is independent of
inflammatory cell recruitment in that lymphocyte and
eosinophil influx to the airways peaks at 48-hours after
allergen challenge whereas AHR peaks at 24-hours [11]. In
agreement with our studies, Corry et al have shown AHR
occurs independently of eosinophil recruitment to the
lung [31].
Exacerbated AHR in C5-deficient animals was first sug-
gested in gene-linkage studies by Karp et al [7] that
showed C5 gene expression inversely correlates with the
magnitude of allergen-induced AHR in an ovalbumin
model of allergic asthma; C5 gene expression was found
to be lower in mouse strains more susceptible to the
development of allergen-induced AHR. More recently,
Kohl et al showed blocking C5aR signaling during initial
allergen priming results in exacerbated TH2 responses and
increased AHR compared to control [32]. It has been sug-
gested that the increased AHR in C5-deficient animals is
Bronchoalveolar lavage tryptase levels Figure 5
Bronchoalveolar lavage tryptase levels. Tryptase levels were 
determined by ELISA in the bronchoalveolar lavage fluid har-
vested at 48 hours after the last intratracheal challenge. C5 
deficient mice had significantly higher levels of then these C5 
sufficient mice. Values represent mean ± SEM with n = 11–15 
for each group. **p < 0.01 compared to C5 Sufficient mice.
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Airway hyperresponsiveness Figure 4
Airway hyperresponsiveness. AHR was assessed 24-hours 
after the last pulmonary challenge in C5-sufficient (solid bars) 
and C5-deficient (diagonal bars) mice. Values are reported as 
the percent increase in Penh of each dose of methylcholine 
relative to PBS aerosolization. Each value is the mean ± SEM 
for three experiments; n = 14 mice per group in three exper-
iments for immunized and challenged mice. * indicates p < 
0.05 for C5-sufficient compared to C5-deficient at each MCh 
dose, p = 0.0026 at the 25 mg/ml MCh dose and p < 0.0001 
at the 50 mg/ml MCh dose.
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due to a skewed immune response in favor of a TH2 phe-
notype; mouse strains deficient in C5 (A/J) have signifi-
cantly decreased IL-12 production from cultured
peritoneal macrophages following IFN-γ + Staphalococcus
aureus (SAC) stimulation compared to cultured macro-
phages isolated from C5-sufficient C3H/HeJ mice. Pri-
mary human monocyte cultures stimulated with IFN-γ +
SAC in the presence of a specific C5aR antagonist showed
a dose-dependent decrease in IL-12 production as well
[7]. Taken together this suggests that C5a signaling
through the C5aR would result in IL-12 production and
Th1-cell differentiation; thus there is an abrogated IL-12
response in C5-deficient animals that may favor Th2-cell
development and potentiate the allergic phenotype. These
studies do not address the in vivo IL-12 response following
allergen stimulation. We report C5-deficient mice immu-
nized and challenged with HDE have significantly
decreased lung homogenate IL-12 at 24-hours but similar
levels of IL-12 in BAL fluid compared to C5-sufficient
mice of the same genetic background. IL-13 in the lung
was also comparable in sufficient and deficient animals at
24- and 48-hours after allergen challenge. These time
points were chosen as optimal for the measurement of
AHR and cellular influx to the airways however, the peak
of cytokine and chemokine production in lung is likely a
much earlier event. It is plausible that the Th1/Th2 bal-
ance is skewed in the early asthmatic response and further
studies to investigate the time course of IL-12 and IL-13
production in the lung need to be performed to determine
if cytokine levels are comparable early after allergen prov-
ocation.
BAL fluid C3 levels Figure 7
BAL fluid C3 levels. C3 levels were measured by ELISA 24 
and 48-hours after the last pulmonary challenge; C5-sufficient 
(solid bars) and C5-deficient (diagonal bars) mice. Each value 
is the mean ± SEM in three experiments for n = 5 mice/group 
at 24-hours and n = 10 mice/group at 48-hours, p > 0.05 for 
C5-sufficient compared to C5-deficient at each time point.
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Pulmonary IL-12 p70 and IL-13 Figure 6
Pulmonary IL-12 p70 and IL-13. BAL fluid and lung homoge-
nate levels of IL-12 p70 and IL-13 were measured 24- and 48-
hours after the last pulmonary challenge by ELISA; C5-suffi-
cient (solid bars) and C5-deficient (diagonal bars) mice. A. 
Lung homogenate IL-12 p70, * indicates p < 0.05 for C5-suffi-
cient compared to C5-deficient at 24-hours. B. BAL fluid IL-
12 p70, p > 0.05 for C5-sufficient compared to C5-deficient 
at each time point. C. Lung homogenate IL-13, p > 0.05 for 
C5-sufficient compared to C5-deficient at each time point. 
BAL fluid IL-13 was below detection for the assay (124 pg/
ml). Each value is the mean ± SEM for three experiments; n = 
5 mice/group at 24-hours and n = 10 mice/group at 48-hours.
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Increased production of cysteinyl-leukotrienes relates to
increased AHR [33,34] and provides a potential mecha-
nism for the substantial increase in AHR seen in C5-defi-
cient mice following allergen provocation. Cysteinyl-
leukotrienes are secreted by activated mast cells, basophils
and eosinophils [35,36]. Studies using W/Wv mice defi-
cient in mast cells have shown the importance of these
cells in allergen-induced AHR. Mast cell deficient animals
immunized and challenged with OVA fail to develop AHR
to MCh challenge but AHR is restored when mast cells are
reconstituted [37,38]. Clinically, basophils and mast cells
accumulate in the airways of asthmatic patients [39]. We
show for the first time that C5-deficient animals have sig-
nificantly increased production of cysteinyl-leukotrienes
in the BAL fluid compared to sufficient controls. Further-
more, we found this enhanced cysteinyl-leukotriene pro-
duction in C5-deficient animals was directly linked to the
substantial increase in AHR seen in these animals. Treat-
ment with the leukotriene inhibitor Montelukast abro-
gated the hyperresponsiveness. These data are interesting
considering previous in vitro studies have found C5a
leads to leukotriene C4 production by basophils [35], and
both C3a and C5a have been shown to stimulate chemo-
taxis of mast cells [20]. Therefore one would expect leuko-
triene production to be decreased in the C5-deficient
mice. The apparent dichotomy of C5aR signaling has been
shown to be dependent on the time of receptor targeting.
C5aR signaling at the time of sensitization has been
reported to protect against the development of allergic
inflammation whereas signaling through C5aR in a pre-
existing inflammatory environment results in enhanced
inflammatory responses. This supports our findings that
the absence of C5a at the time of sensitization results in
exacerbated allergic inflammatory responses [32].
The mechanism of cysteinyl-leukotriene production in
C5-deficient mice is not clear from these studies and
requires further investigation. Total plasma IgE is compa-
rable in sufficient and deficient animals suggesting
enhanced leukotriene production is not mediated
through FcεRI. One explanation is that the degree of C3
Montelukast significantly reduces airway hyperresponsive- ness Figure 9
Montelukast significantly reduces airway hyperresponsive-
ness. Penh values were obtained from mice 24 hours after 
the last challenge in response to nebulized MCh via whole 
body plethysmography. The data are expressed as the mean 
± SEM of Penh values (n = 3–4) as the increased percentage 
of baseline observed after PBS nebulization. * p < 0.05 and ** 
p < 0.01 when compared to PBS-treated group.
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Cysteinyl-leukotriene and IgE production Figure 8
Cysteinyl-leukotriene and IgE production. A. Cysteinyl-leuko-
trienes were measured by immunoassay 24 and 48-hours 
after the last pulmonary challenge; C5-sufficient (solid bars) 
and C5-deficient (diagonal bars) mice. * indicates p < 0.05 for 
C5-sufficient compared to C5-deficient at the indicated time 
point, p = 0.015 at 24-hours and p = 0.003 at 48-hours. B. 
Total plasma IgE was determined by ELISA. Each value is the 
mean ± SEM for three experiments; n = 5 mice/group at 24-
hours and n = 10 mice/group at 48-hours, p > 0.05 for C5-
sufficient compared to C5-deficient at each time point.
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activation is increased in animals deficient in C5. C3-defi-
cient and C3aR-deficient mice have decreased pulmonary
inflammation, Th2 cytokine production, and AHR in OVA
models of allergic pulmonary inflammation and attenu-
ated particulate matter-induced AHR [3-6,40]. These stud-
ies consistently show C3a is an important mediator of
AHR. C3a binding to C3aR on mast cells and basophils
could activate these cells to release inflammatory media-
tors including leukotrienes. We saw similar levels of C3
protein in the BAL fluid of sufficient and deficient animals
after allergen challenge at 24- and 48-hours after allergen
challenge and further investigation into the levels of C3
and C3a in C5-sufficient and C5-deficient animals is
planned.
Alternatively, C5a and C3a may have differential roles in
the allergic inflammatory response. As suggested by
Hawlisch et al [22], C5a binding to C5aR results in IL-12
production while C3 binding C3aR favors Th2 cytokine
production. This would explain contrasting results with
C3-deficient animals and C5-deficient animals in models
of allergic asthma. Previous investigators have also dem-
onstrated that blockade of C5a will reduce late airways
hyper-reactivity in an ovalbumin model [41], inhibition
of complement activation also reduced airways hyper-
reactivity in the ovalbumin model [42], and blockade of
C5a receptors reduced airways responsiveness in an
Aspergillus model [43]. The differences in experimental
design between these previous reports and our studies and
those of Karp [7] probably account for the divergent
results. Karp's studies plus our own used genetically mod-
ified mice while the other papers inhibited complement
only during the effector phase of asthma.
In conclusion, we have shown C5-deficient mice immu-
nized and challenged with HDE containing high levels of
cockroach allergens exhibit dramatically increased AHR.
This AHR occurs independently of pulmonary cellular
infiltration and does not appear to be the result of a
skewed immune response as seen by comparable produc-
tion of IL-12 in sufficient and deficient animals. It remains
possible that C5-deficient mice have an abrogated IL-12
response and enhanced IL-13 production in the early
phase of the asthmatic response resulting in the increased
cysteinyl-leukotriene production; future studies where
mice will be sacrificed in the early phase are thus planned.
Increased levels of BAL fluid cysteinyl-leukotrienes seen in
C5-deficient mice provide a logical mechanism for the
increased level of AHR.
Abbreviations
AHR, airway hyperresponsiveness; BAL, bronchoalveolar
lavage; HDE, house dust extract; MCh, acetyl β-methyl-
choline; Penh, enhanced pause;
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